Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Breast Cancer Research : BCR
|
December 22, 2010
Deciding priorities in Pharma
Maria Koehler
Journal of Pediatric Hematology/Oncology
|
October 9, 2002
Diminished antibody response to hepatitis B immunization in children with sickle cell disease
Jeffrey Hord, Beth Windsor, Maria Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2009
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Richard S Finn, Robert Gagnon, Angelo Di Leo, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Anti-Cancer Drugs
|
March 12, 2004
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839)
Andreas Schneeweiss, Sema Kolay, Sebastian Aulmann, et al.
Cancer Discovery
|
April 2, 2021
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Jeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer
Richard S Finn, Michael F Press, Judy Dering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
Leona Downey, Robert B Livingston, Maria Koehler, et al.
Breast Cancer Research and Treatment
|
January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P Crown, Harold A Burris, Fran Boyle, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
January 17, 2015
Cell Index Database (CELLX): a web tool for cancer precision medicine
Keith A Ching, Kai Wang, Zhengyan Kan, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Breast Cancer Research : BCR
|
December 22, 2010
Deciding priorities in Pharma
Maria Koehler
Journal of Pediatric Hematology/Oncology
|
October 9, 2002
Diminished antibody response to hepatitis B immunization in children with sickle cell disease
Jeffrey Hord, Beth Windsor, Maria Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2009
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Richard S Finn, Robert Gagnon, Angelo Di Leo, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Anti-Cancer Drugs
|
March 12, 2004
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839)
Andreas Schneeweiss, Sema Kolay, Sebastian Aulmann, et al.
Cancer Discovery
|
April 2, 2021
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Jeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer
Richard S Finn, Michael F Press, Judy Dering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
Leona Downey, Robert B Livingston, Maria Koehler, et al.
Breast Cancer Research and Treatment
|
January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P Crown, Harold A Burris, Fran Boyle, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
January 17, 2015
Cell Index Database (CELLX): a web tool for cancer precision medicine
Keith A Ching, Kai Wang, Zhengyan Kan, et al.
Page
of 4